Patterns of initiation of oral anticoagulants in patients with atrial fibrillation- quality and cost implications.

[1]  H. Vidaillet,et al.  Meta-analysis of randomized controlled trials on risk of myocardial infarction from the use of oral direct thrombin inhibitors. , 2013, The American journal of cardiology.

[2]  J. Jansson,et al.  Estimating the prevalence of atrial fibrillation in a general population using validated electronic health data , 2013, Clinical epidemiology.

[3]  D. Singer,et al.  Early Adoption of Dabigatran and Its Dosing in US Patients With Atrial Fibrillation: Results From the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation , 2013, Journal of the American Heart Association.

[4]  E. Antman,et al.  Edoxaban versus warfarin in patients with atrial fibrillation. , 2013, The New England journal of medicine.

[5]  T. Brennan,et al.  Cost-Effectiveness of Oral Anticoagulants for Treatment of Atrial Fibrillation , 2013, Circulation. Cardiovascular quality and outcomes.

[6]  G. Merli,et al.  Evaluation of the oral direct factor Xa inhibitor – betrixaban , 2013, Expert opinion on investigational drugs.

[7]  J. Kluger,et al.  Novel Anticoagulants for Stroke Prevention in Atrial Fibrillation: A Systematic Review of Cost-Effectiveness Models , 2013, PloS one.

[8]  Marsha E Reichman,et al.  Dabigatran and postmarketing reports of bleeding. , 2013, The New England journal of medicine.

[9]  T. Gomes,et al.  Persistence with therapy among patients treated with warfarin for atrial fibrillation. , 2012, Archives of internal medicine.

[10]  Gerhard Hindricks,et al.  2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation--developed with the special contribution of the European Heart Rhythm Association. , 2012, Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology.

[11]  K. Mak.  Coronary and mortality risk of novel oral antithrombotic agents: a meta-analysis of large randomised trials , 2012, BMJ Open.

[12]  R. Stafford,et al.  National Trends in Oral Anticoagulant Use in the United States, 2007 to 2011 , 2012, Circulation. Cardiovascular quality and outcomes.

[13]  W. Winkelmayer,et al.  Prevalence of atrial fibrillation and warfarin use in older patients receiving hemodialysis. , 2012, Journal of nephrology.

[14]  D. Atar,et al.  Apixaban versus warfarin in patients with atrial fibrillation. , 2011, The New England journal of medicine.

[15]  Kenneth A Ellenbogen,et al.  2011 ACCF/AHA/HRS focused update on the management of patients with atrial fibrillation (update on Dabigatran): a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. , 2011, Circulation.

[16]  Kenneth A Ellenbogen,et al.  2011 ACCF/AHA/HRS focused update on the management of patients with atrial fibrillation (updating the 2006 guideline): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. , 2011, Circulation.

[17]  B. Gage,et al.  Cost-Effectiveness of Dabigatran for Stroke Prophylaxis in Atrial Fibrillation , 2010, Circulation.

[18]  Gregory Y H Lip,et al.  A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey. , 2010, Chest.

[19]  Gregory Y H Lip,et al.  Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation. , 2010, Chest.

[20]  S. Yusuf,et al.  Dabigatran versus warfarin in patients with atrial fibrillation. , 2009, The New England journal of medicine.

[21]  M. Rich,et al.  Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation. , 2001, JAMA.

[22]  JerryAvorn.  The Promise of Pharmacoepidemiology in Helping Clinicians Assess Drug Risk , 2013 .

[23]  R. Troughton,et al.  Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. , 2011, The New England journal of medicine.